Regardless of which side of the hiring table you're sitting at, these are the skills startup and SMB employees need to have. Photo via Getty Imahes

As an executive recruiter, two questions I regularly receive are how to get a role in a SMB fast growth company after having been in a larger, and oftentimes global organization for a significant amount of time, or how to change career paths — whether it’s into another department (e.g., operations to sales) or breaking into a different industry altogether (quite frequently from oil and gas to the tech space).

I have helped several candidates successfully navigate one or all of those scenarios, but also was able to do so myself when I transitioned from owning a booking agency in the beauty industry. And in my experience, those who were able to leverage transferable skills, provided their new employers with a unique perspective and significantly broader lens, especially in terms of strategy.

With the state of our economy influx — as some industries announce layoffs and others continue to experience labor shortages — I have culled together the following tips for hirers and job seekers alike.

First of all, let's identify the traits of someone well suited for SMB or startup culture:

  • Tenacious, a self starter, and someone who thrives on being busy at work.
  • Revered as a go-to person. When leadership needs something done, this is the team member they know they can rely on to do it well and on time.
  • Volunteers to step outside their comfort zone and take on new responsibilities.
  • Intellectually curious and thrives on learning new things.
  • Identifies problems, but also takes initiative to solve them or recognize workarounds without expecting someone else to.

Looking to break into the startup scene? Consider highlighting and/or acquiring these industry agnostic skills:

Conviction

I always recommend people interviewing for any position create a “verbal resume” or addendum to accompany their traditional one. These are examples of projects or scenarios you successfully navigated in past roles that make the case for your ability to meet the prospective employer’s expectations.

Job descriptions often list the most important requirements first. Identify similar skills that were expected in your previous positions and examples to cite in conversation. I also recommend briefly bullet-pointing the most impressive ones on the resume. Going through this process will help you personally identify if you are able to confidently take on the position.

We often undervalue certain perspectives we might bring to a role if they are something that comes easily or is done regularly. Do not assume hiring companies know your role-relevant skills and do not be afraid to share notable accomplishments.

Steadfast

Smaller companies often rely on positions having wider scopes than at their larger counterparts. This requires worker flexibility instead of sticking to a rigidly defined role.

As a recruiter, I am hesitant about placing candidates with experience only from larger organizations where typically people are not required to wear as many hats. Smaller companies require people to be self starters and to exemplify tenacity in order to make it through the messiness that fast growth startups often possess. It is exciting, challenging, and rewarding for the right person.

Be able to identify times you were proactive, especially if you identified a problem or a breakdown in process, developed a solution, and then executed it. With fast growth, this has to happen often to support scale. There is not the luxury of going to senior leaders and saying, “I cannot do my role because of this problem and I need it fixed.” They need candidates who are able to identify issues, but who also love the opportunity to fix them. Especially if you used to working in a corporate environment, identify times you raised your hand to take on something that was not required, initiated opportunities to collaborate with new teams, or stepped outside your comfort zone.

Pliable

Be flexible around compensation, especially if breaking into a new industry. I almost never recommended a lateral move in compensation, and even less so, a step down. But it is important to acknowledge that there are exceptions. If you are changing industries or breaking into a new part of the company altogether (e.g., engineering to sales), you will need to expect to not be compensated similarly to others who may have as many years of work as you but more experience in the specific role/industry.

The company is taking a risk on you and knows there will be a learning curve. For the right candidate, that assimilation will be quick and compensation will eventually balance out. Smaller companies in startup mode can sometimes find it challenging to compete with larger organizations’ salaries, especially if a candidate has a longer tenure (7 to 10 years or more) at the same company.

At the executive level though, the reward of gaining experience and successfully navigating the startup scene, can pay off exponentially in the long term for people especially in equity bearing roles. Oftentimes, I have seen candidates make the move and initially the role does not offer equity or additional incentives. However, over time, their performance can be rewarded with it.

While other SMBs might believe you will make the transition successfully and may offer packages with it from the get go. Where this recommendation gets sticky is candidates historically do not stay in a role very long if they have a reduction in pay. It is much easier to say you can do without for a period of time than to actually do it. Carefully assess if a cut is something your budget can truly bear.

------

Leah Salinas is a managing director with Houston-based executive hiring firm Sudduth Search LLC.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.